-$0.18 EPS Expected for Galena Biopharma, Inc. (NYSE:SLS) This Quarter

Brokerages expect that Galena Biopharma, Inc. (NYSE:SLS) will announce ($0.18) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Galena Biopharma’s earnings. Galena Biopharma reported earnings of ($1.26) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 85.7%. The firm is expected to announce its next earnings results on Wednesday, August 21st.

According to Zacks, analysts expect that Galena Biopharma will report full-year earnings of ($0.85) per share for the current financial year. For the next fiscal year, analysts forecast that the business will report earnings of ($0.99) per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Galena Biopharma.

Galena Biopharma (NYSE:SLS) last released its earnings results on Wednesday, May 15th. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.06.

Shares of SLS remained flat at $$0.14 during mid-day trading on Tuesday. 50,385,605 shares of the stock traded hands, compared to its average volume of 6,595,634. The stock’s fifty day moving average is $0.30. Galena Biopharma has a 12 month low of $0.10 and a 12 month high of $2.46.

Galena Biopharma Company Profile

Develop biopharmaceuticals

Further Reading: What is Cost of Debt?

Get a free copy of the Zacks research report on Galena Biopharma (SLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Galena Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.